-DOCSTART- -X- O
Angiotensin-converting -X- _ B-Intervention
enzyme -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
ACE2 -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
expressed -X- _ O
in -X- _ O
the -X- _ O
kidney -X- _ O
and -X- _ O
may -X- _ O
be -X- _ O
a -X- _ O
renoprotective -X- _ O
enzyme -X- _ O
, -X- _ O
since -X- _ O
it -X- _ O
converts -X- _ O
angiotensin -X- _ O
( -X- _ O
Ang -X- _ O
) -X- _ O
II -X- _ O
to -X- _ O
Ang- -X- _ O
( -X- _ O
1-7 -X- _ O
) -X- _ O
. -X- _ O
ACE2 -X- _ O
has -X- _ O
been -X- _ O
detected -X- _ O
in -X- _ O
urine -X- _ O
from -X- _ O
patients -X- _ O
with -X- _ O
chronic -X- _ O
kidney -X- _ O
disease. -X- _ O
We -X- _ O
measured -X- _ O
urinary -X- _ B-Intervention
ACE2 -X- _ I-Intervention
activity -X- _ I-Intervention
and -X- _ I-Intervention
protein -X- _ I-Intervention
levels -X- _ I-Intervention
in -X- _ O
renal -X- _ B-Patient
transplant -X- _ I-Patient
patients -X- _ I-Patient
( -X- _ I-Patient
age -X- _ I-Patient
54 -X- _ I-Patient
yrs -X- _ I-Patient
, -X- _ I-Patient
65 -X- _ I-Patient
% -X- _ I-Patient
male -X- _ I-Patient
, -X- _ I-Patient
38 -X- _ I-Patient
% -X- _ I-Patient
diabetes -X- _ I-Patient
, -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
100 -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
healthy -X- _ B-Comparison
controls -X- _ I-Comparison
( -X- _ I-Comparison
age -X- _ I-Comparison
45 -X- _ I-Comparison
yrs -X- _ I-Comparison
, -X- _ I-Comparison
26 -X- _ I-Comparison
% -X- _ I-Comparison
male -X- _ I-Comparison
, -X- _ I-Comparison
n -X- _ I-Comparison
= -X- _ I-Comparison
50 -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ O
and -X- _ O
determined -X- _ O
factors -X- _ O
associated -X- _ O
with -X- _ O
elevated -X- _ B-Outcome
urinary -X- _ I-Outcome
ACE2 -X- _ I-Outcome
in -X- _ O
the -X- _ O
patients. -X- _ O
Urine -X- _ O
from -X- _ O
transplant -X- _ O
subjects -X- _ O
was -X- _ O
also -X- _ O
assayed -X- _ O
for -X- _ O
ACE -X- _ O
mRNA -X- _ O
and -X- _ O
protein. -X- _ O
No -X- _ O
subjects -X- _ O
were -X- _ O
taking -X- _ O
inhibitors -X- _ O
of -X- _ O
the -X- _ O
renin-angiotensin -X- _ O
system. -X- _ O
Urinary -X- _ B-Outcome
ACE2 -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
transplant -X- _ I-Outcome
patients -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
controls -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.003 -X- _ I-Outcome
for -X- _ I-Outcome
ACE2 -X- _ I-Outcome
activity -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
pâ‰¤0.001 -X- _ I-Outcome
for -X- _ I-Outcome
ACE2 -X- _ I-Outcome
protein -X- _ I-Outcome
by -X- _ I-Outcome
ELISA -X- _ I-Outcome
or -X- _ I-Outcome
western -X- _ I-Outcome
analysis -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Transplant -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
diabetes -X- _ I-Outcome
mellitus -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
urinary -X- _ I-Outcome
ACE2 -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
protein -X- _ I-Outcome
levels -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
non- -X- _ I-Outcome
diabetics -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
ACE2 -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
differ. -X- _ I-Outcome
Urinary -X- _ I-Outcome
ACE -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
protein -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
in -X- _ I-Outcome
diabetic -X- _ I-Outcome
transplant -X- _ I-Outcome
subjects -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
ACE -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
differ -X- _ I-Outcome
from -X- _ I-Outcome
non-diabetic -X- _ I-Outcome
subjects. -X- _ I-Outcome
After -X- _ I-Outcome
adjusting -X- _ I-Outcome
for -X- _ I-Outcome
confounding -X- _ I-Outcome
variables -X- _ I-Outcome
, -X- _ I-Outcome
diabetes -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
urinary -X- _ I-Outcome
ACE2 -X- _ I-Outcome
activity -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.003 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
protein -X- _ I-Outcome
levels -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
female -X- _ I-Outcome
gender -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
urinary -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
for -X- _ I-Outcome
both -X- _ I-Outcome
ACE2 -X- _ I-Outcome
and -X- _ I-Outcome
ACE. -X- _ I-Outcome
These -X- _ O
data -X- _ O
indicate -X- _ O
that -X- _ O
urinary -X- _ B-Outcome
ACE2 -X- _ I-Outcome
is -X- _ I-Outcome
increased -X- _ I-Outcome
in -X- _ I-Outcome
renal -X- _ I-Outcome
transplant -X- _ I-Outcome
recipients -X- _ I-Outcome
with -X- _ I-Outcome
diabetes -X- _ I-Outcome
, -X- _ O
possibly -X- _ O
due -X- _ O
to -X- _ O
increased -X- _ O
shedding -X- _ O
from -X- _ O
tubular -X- _ O
cells. -X- _ O
Urinary -X- _ B-Intervention
ACE2 -X- _ I-Intervention
could -X- _ O
be -X- _ O
a -X- _ O
marker -X- _ O
of -X- _ O
renal -X- _ O
renin-angiotensin -X- _ O
system -X- _ O
activation -X- _ O
in -X- _ O
these -X- _ O
patients -X- _ O
. -X- _ O

